Clinical trial · Interventional
Individualized Pharmaceutical-care in Outpatients With Cancer Pain
Impact of Individualized Pharmaceutical-care on Medication Adherence and Outcome of Cancer Pain in Opioid-tolerant Outpatients
NCT03439904CI-TRIAL-00036536unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant outpatients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pharmaceutical care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- pharmaceutical care intervention group
- description
- Patients will receive individualized pharmaceutical care in addition to usual medical care
- interventionNames
- Other: Pharmaceutical care
- type
- NO_INTERVENTION
- label
- control group
- description
- Patients will receive usual medical care
Primary outcomes (1)
- measure
- Change in medication adherence
- timeFrame
- Change from baseline at 1 month
- description
- The investigators will measure the change in medication adherence via Morisky Scale from baseline to 1 months. Morisky Scale contains 4 questions, and the total score ranges from 0 to 4 with lower scores indicating higher adherence.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 years or older; * Histologically confirmed solid tumor; * Diagnosed chronic cancer pain; * Opioid-tolerant patients; * Overall survival is expected to be over 3 months; * Karnofsky performance score≥50; * Willing and able to comply with the protocol Exclusion Criteria: * Patients aged 18 years or older; * Histologically confirmed solid tumor; * Diagnosed chronic cancer pain; * Opioid-tolerant patients; * Overall survival is expected to be over 3 months; * Karnofsky performance score≥50; * Willing and able to comply with the protocol
References
Publications (1)
- DERIVEDDing H, Song Y, Wu N, Zheng X, Wei Q, Sun Y, Xie R, Zhai Q, Xu S, Qi Y, Wang Y, Li H, Yang L, Fan Q, Zhao Q, Chen J, Shi J, Duan C, Du Q, Zhang Y, Song Z, Fu S, Cai Y, Huang X, Fang L, Liu Y, Huang P. Impact of individualized pharmaceutical care on efficacy and safety of opioid-tolerant outpatients with cancer pain: a multicenter randomized controlled trial. Ann Transl Med. 2022 Sep;10(18):989. doi: 10.21037/atm-22-4091. PMID 36267757